RFS Failed as Endpoint in Adjuvant Immunotherapy Trials

A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.
Medscape Medical News

source https://www.medscape.com/viewarticle/994971?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost